Syros Pharmaceuticals Analyst Ratings
Syros Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 137.3% | Piper Sandler | $11 → $7 | Maintains | Overweight |
| 08/09/2023 | 408.51% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/11/2023 | 408.51% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/11/2023 | 408.51% | JMP Securities | $16 → $15 | Maintains | Market Outperform |
| 03/03/2023 | 340.71% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 03/03/2023 | 408.51% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 01/05/2023 | 578.01% | Piper Sandler | $27 → $20 | Maintains | Overweight |
| 11/15/2022 | 442.41% | JMP Securities | $40 → $16 | Maintains | Market Outperform |
| 11/15/2022 | 408.51% | Oppenheimer | $30 → $15 | Maintains | Outperform |
| 11/15/2022 | 578.01% | HC Wainwright & Co. | $6 → $20 | Maintains | Buy |
| 08/10/2022 | 1.7% | Oppenheimer | $9 → $3 | Maintains | Outperform |
| 07/12/2022 | 103.4% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 05/17/2022 | 239.01% | HC Wainwright & Co. | $15 → $10 | Maintains | Buy |
| 05/17/2022 | 239.01% | Alliance Global Partners | $14 → $10 | Maintains | Buy |
| 09/23/2021 | 679.71% | Roth Capital | $20 → $23 | Maintains | Buy |
| 11/04/2020 | 408.51% | HC Wainwright & Co. | $11 → $15 | Upgrades | Neutral → Buy |
| 03/06/2020 | 171.2% | HC Wainwright & Co. | $10 → $8 | Reiterates | → Neutral |
| 01/17/2020 | 205.11% | Wedbush | → $9 | Downgrades | Outperform → Neutral |
| 10/18/2019 | 442.41% | JMP Securities | $18 → $16 | Maintains | Market Outperform |
| 02/14/2019 | — | Oppenheimer | Assumes | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/03/2023 | 137.3% | 派珀·桑德勒 | $11→$7 | 維護 | 超重 |
| 08/09/2023 | 408.51% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 2023年05月11日 | 408.51% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 2023年05月11日 | 408.51% | JMP證券 | $16→$15 | 維護 | 市場表現強於大盤 |
| 03/03/2023 | 340.71% | 奧本海默 | $15→$13 | 維護 | 跑贏大盤 |
| 03/03/2023 | 408.51% | HC Wainwright公司 | →$15 | 重申 | →購買 |
| 01/05/2023 | 578.01% | 派珀·桑德勒 | $27→$20 | 維護 | 超重 |
| 2022年11月15日 | 442.41% | JMP證券 | $40→$16 | 維護 | 市場表現強於大盤 |
| 2022年11月15日 | 408.51% | 奧本海默 | $30→$15 | 維護 | 跑贏大盤 |
| 2022年11月15日 | 578.01% | HC Wainwright公司 | $6→$20 | 維護 | 買 |
| 2022年08月10日 | 1.7% | 奧本海默 | $9→$3 | 維護 | 跑贏大盤 |
| 07/12/2022 | 103.4% | HC Wainwright公司 | $10→$6 | 維護 | 買 |
| 2022/05/17 | 239.01% | HC Wainwright公司 | $15→$10 | 維護 | 買 |
| 2022/05/17 | 239.01% | 聯盟全球合作夥伴 | $14→$10 | 維護 | 買 |
| 09/23/2021 | 679.71% | 羅斯資本 | $20→$23 | 維護 | 買 |
| 11/04/2020 | 408.51% | HC Wainwright公司 | $11→$15 | 升級 | 中性→購買 |
| 03/06/2020 | 171.2% | HC Wainwright公司 | $10→$8 | 重申 | →中性 |
| 2020/01/17 | 205.11% | 韋德布什 | →$9 | 評級下調 | 跑贏→中性 |
| 2019年10月18日 | 442.41% | JMP證券 | $18→$16 | 維護 | 市場表現強於大盤 |
| 2019年02月14日 | - | 奧本海默 | 假設 | →跑贏大盤 |
What is the target price for Syros Pharmaceuticals (SYRS)?
Syros PharmPharmticals(SYRS)的目標價是多少？
The latest price target for Syros Pharmaceuticals (NASDAQ: SYRS) was reported by Piper Sandler on October 3, 2023. The analyst firm set a price target for $7.00 expecting SYRS to rise to within 12 months (a possible 137.30% upside). 10 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年10月3日報道了賽洛斯製藥(納斯達克：SYRS)的最新目標價。這家分析公司將目標價定為7美元，預計SYR將在12個月內升至(可能上漲137.30%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Syros Pharmaceuticals (SYRS)?
分析師對Syros PharmPharmticals(SYRS)的最新評級是多少？
The latest analyst rating for Syros Pharmaceuticals (NASDAQ: SYRS) was provided by Piper Sandler, and Syros Pharmaceuticals maintained their overweight rating.
納斯達克(Sequoia Capital：SYRS)的最新分析師評級由Piper Sandler提供，Syros PharmPharmticals維持增持評級。
When is the next analyst rating going to be posted or updated for Syros Pharmaceuticals (SYRS)?
Syros PharmPharmticals(SYRS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Syros製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Syros製藥的上一次評級是在2023年10月3日提交的，所以你應該預計下一次評級將在2024年10月3日左右的某個時候公佈。
Is the Analyst Rating Syros Pharmaceuticals (SYRS) correct?
分析師對Syros PharmPharmticals(SYRS)的評級正確嗎？
While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a maintained with a price target of $11.00 to $7.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $2.95, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Syros PharmPharmticals(SYRS)的最新評級保持不變，目標價在11.00美元至7.00美元之間。Syros PharmPharmticals(SYRS)目前的交易價格為2.95美元，超出了分析師的預測區間。